A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens

被引：0
|
作者：
Scambia, G.
Parma, G.
Del Conte, G.
Hess, D.
Gadducci, A.
Katsaros, D.
Sessa, C.
Trudel, G. C.
Coceani, N.
Colombo, N.
机构：
[1] Univ Cattolica Sacro Cuore, Campobasso, Italy
[2] Ist Europeo Oncol, Milan, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Kantonsspital St Gallen, St Gallen, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Univ Turin, Turin, Italy
[7] Osped San Giovanni Bellinzona, Bellinzona, Switzerland
[8] Johnson & Johnson, Beerse, Belgium
[9] Sendo, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin
    Grenader, Tal
    Rosengarten, Ora
    Isacson, Rut
    Plotkin, Yevgeni
    Gabizon, Alberto
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2012, 3 (10): : 137 - 141
  • [32] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] A phase II study of pegylated liposomal doxorubicin (PLD), and cyclophosphamide (CTX) as second line therapy in platinum resistant ovarian cancer (OC) patients
    Montesinos, J.
    Losa, F.
    Gallego, O.
    Eres, N.
    Balil, A.
    Franquesa, R.
    Gonzalez, S.
    Cirera, J.
    ANNALS OF ONCOLOGY, 2004, 15 : 130 - 130
  • [34] Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer
    Strauss, Hans-Georg
    Hemsen, Alice
    Karbe, Ina
    Lautenschlaeger, Christine
    Persing, Monika
    Thomssen, Christoph
    ANTI-CANCER DRUGS, 2008, 19 (05) : 541 - 545
  • [35] Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients
    Jacquin, Jean-Philippe
    Chargari, Cyrus
    Thorin, Julie
    Mille, Dominique
    Melis, Adrien
    Orfeuvre, Hubert
    Clavreul, Guillaume
    Chaigneau, Loic
    Nourissat, Alice
    Dumanoir, Chantal
    Savary, Jacqueline
    Merrouche, Yacine
    Magne, Nicolas
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 18 - 21
  • [36] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
  • [37] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [38] Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
    Villanucci, Alessandro
    Tavella, Ketty
    Vannini, Laura
    Rossi, Virginia
    Nobili, Stefania
    Amunni, Gianni
    Mazzei, Teresita
    Mini, Enrico
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 635 - 639
  • [39] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Zhen Yuan
    Ying Zhang
    Dongyan Cao
    Keng Shen
    Qingshui Li
    Guonan Zhang
    Xiaohua Wu
    Manhua Cui
    Ying Yue
    Wenjun Cheng
    Li Wang
    Pengpeng Qu
    Guangshi Tao
    Jianqing Hou
    Lixin Sun
    Yuanguang Meng
    Guiling Li
    Changzhong Li
    Huirong Shi
    Yaqing Chen
    Journal of Ovarian Research, 14
  • [40] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
12345